December 14, 2015 / 3:16 PM / 3 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Trina, NephroGenex, Atara

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter,; for the Morning News Call newsletter, Wall Street was little changed on Monday, two days ahead of an expected U.S. interest rate hike, as crude oil prices hovered near 11-year lows. The Dow Jones industrial average was down 0.31 percent at 17,211.56, the S&P 500 was down 0.32 percent at 2,005.92 and the Nasdaq Composite was down 0.31 percent at 4,918.002.

** TRINA SOLAR LTD, $10.61, +11.10 pct

The Chinese solar panel maker said on Monday it received a preliminary proposal from its chief executive and Shanghai Xingsheng Equity Investment & Management Co to take the company private.

** ATARA BIOTHERAPEUTICS INC, $23.3, -29.82 pct

The drug developer said it would stop developing its kidney drug after the treatment failed to meet the main goal of a mid-stage study.

** APPLE INC, $110.87, -2.04 pct

Barclays and Morgan Stanley cut their price targets on the IPhone maker’s stock. Morgan Stanley analysts in a note on Sunday said IPhone unit sales are expected to fall about 6 percent in FY16 as higher prices in markets outside the Americas, excluding China, and maturing smartphone penetration in developed markets weigh on upgrades and new user growth.

** GOPRO INC, $16.854, -11.99 pct

Citigroup cut its rating on the wearable camera maker’s stock to “neutral” from “buy” on Friday. It also slashed its price target to $22 from $75. Citigroup analysts said they had thought GoPro would recover from poor sales of Hero 4 Session but now think demand for GoPro products is softening.

Morgan Stanley also cut its rating to “underweight” from “equal-weight”.

** NEPHROGENEX INC, $2.3699, +64.58 pct

The drug developer says the U.S. FDA allows human testing of its experimental drug to treat acute kidney injury. The drug is designed to reduce kidney injury, post-injury tissue scarring and improve kidney function recovery.

** JARDEN CORP, $54.72, +3.87 pct

** NEWELL RUBBERMAID INC, $42.48, -6.18 pct

Newell Rubbermaid, the maker of Sharpie markers and Parker pens, agreed to buy diversified consumer products company Jarden Corp for $13.22 billion, adding brands such as Sunbeam kitchen appliances and Coleman outdoor gear.

** TWITTER INC, $24.44, -1.61 pct

The micro blogging site issued an alert to some users warning them that state-sponsored hackers may have tried to obtain sensitive data from their accounts, the company said, the first such warning by twitter.

** KINDER MORGAN, $16.01, -3.90 pct

The oil and gas pipeline operator shares do not appear cheap despite having fallen 60 percent this year, and could fall further before reaching fair value, U.S. weekly investment publication Barron’s said in its Dec. 14 edition.

** DOW CHEMICAL CO, $51.15, -4.16 pct

** DUPONT CO, $67.39, -4.33 pct

Activist investor Daniel Loeb of hedge fund Third Point has called for the removal of Dow Chemical Chief Executive Officer Andrew Liveris after the company’s agreement to merge with DuPont, the Wall Street Journal reported on Sunday.

** ENCANA CORP, $5.49, -9.11 pct

The Canadian oil and natural gas producer, responding to a sharp drop in oil prices, has slashed its dividend by about 79 percent and its 2016 capital budget by more than a quarter.

** HORIZON PHARMA, $19.39, +2.11 pct

The specialty drug maker said on Friday it has agreed to buy Crealta Holdings for $510 million in cash, adding the only U.S.-approved treatment for a type of arthritis to its portfolio.

** TESLA MOTORS, $219.445, +1.12 pct

** SOLAREDGE, $20.6, +3.52 pct

Goldman Sachs’ top picks for stocks that would benefit from an agreement over the weekend at the Paris global climate summit included electric car company Tesla and solar panel group SolarEdge. (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below